Remogliflozin-etabonate-d7-GSK189075-d-sub-7-sub-生命科学试剂-MCE

Hotline:400-820-3792Inhibitors•ScreeningLibraries•Proteinswww.MedChemERemogliflozinetabonate-d7Cat.No.:HY-166548SCASNo.:1233515-93-9Synonyms:GSK189075-d7分⼦式:C₂₆H₃₁D₇N₂O₉分⼦量:529.63作⽤靶点:Isotope-LabeledCompounds;SGLT作⽤通路:Others;MembraneTransporter/IonChannel储存⽅式:PleasestoretheproductundertherecommendedconditionsintheCertificateofAnalysis.BIOLOGICALACTIVITY⽣物活性Remogliflozinetabonate-d7(GSK189075-d7)氘代标记的Remogliflozinetabonate。Remogliflozinetabonate(GSK189075)⼀种具有⼝服活性的，选择性和低亲和⼒的钠葡萄糖共转运蛋⽩(SGLT2)抑制剂，对hSGLT2，rSGLT2，hSGLT1，rSGLT1的Ki值分别为1.95μM，43.1μM，2.14μM，8.57μM。Remogliflozinetabonate⼀种于苄吡唑葡糖苷的前体，在体内被代谢成其活性形式，瑞格列净(Remogliflozin)。Remogliflozinetabonate在啮齿动物模型中显⽰出抗糖尿病功效。体外研究Stableheavyisotopesofhydrogen,carbon,andotherelementshavebeenincorporatedintodrugmolecules,largelyastracersforquantitationduringthedrugdevelopmentprocess.Deuterationhasgainedattentionbecauseofitspotentialtoaffectthepharmacokineticandmetabolicprofilesofdrugs.REFERENCES[1].YoshikazuFujimori,etal.RemogliflozinEtabonate,inaNovelCategoryofSelectiveLow-AffinitySodiumGlucoseCotransporter(SGLT2)Inhibitors,ExhibitsAntidiabeticEfficacyinRodentModels.JPharmacolExpTher.2008Oct;327(1):268-76.McePdfHeightCaution:Producthasnotbeenfullyvalidatedformedicalapplications.Forresearchuseonly.Tel:400-820-3792ax:021-